Efficacy and safety of lasilactone, a new combination diuretic, in essential hypertension.
1. Lasilactone, a new combination diuretic (furosemide 20 mg and spironolactone 50 mg) was evaluated in 30 patients with mild-to-moderate essential hypertension. Each patient received one capsule of lasilactone daily. 2. Significant changes in BP were observed 1 week after initiation of therapy and were sustained during the observation period of 1 year. 3. Supine and standing BP fell from 148.6 +/- 2.6/102.1 +/- 1.9 to 120.8 +/- 1.4/91.7 +/- 1.2 and from 154.4 +/- 2.1/106.1 +/- 1.6 to 125.7 +/- 2.2/90.7 +/- 1.5 mm Hg respectively. 4. There were no changes in the concentrations of plasma glucose, lipids, uric acid and potassium. On the other hand, levels of plasma renin activity rose from 0.69 +/- 0.06 to 3.95 +/- 0.47 ng/ml/hr and urinary aldosterone excretory rate increased from 9.6 +/- 1.6 to 42.8 +/- 4.2 micrograms/day. 5. This study suggests that addition of spironolactone to furosemide improves the hypotensive potency and minimizes the metabolic and electrolyte alterations of the latter.
Birbari
A E
AE
Department of Medicine, American University Medical Center, Beirut, Lebanon.
Daouk
M M
MM
Mukaddam-Daher
S
S
D000328:Adult; D000450:Aldosterone / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011674:Pulse / Q000187:drug effects; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; C048998:lasilacton; D013148:Spironolactone; D000450:Aldosterone; D005665:Furosemide; D012083:Renin; D011188:Potassium